Entrada Therapeutics, Inc. (TRDA) is progressing multiple clinical programs targeting rare neuromuscular diseases through its proprietary Endosomal Escape Vehicle platform enabling intracellular delivery of oligonucleotide therapeutics. The lead DMD exon-skipping candidates are in Phase 1/2 trials with expected mid-2026 data readouts. Collaborations with Vertex advance development in myotonic dystrophy. Despite regulatory milestones including FDA Rare Pediatric Disease Designation, Entrada reported a steep decline in operating and net income for FY2025, continuing its pattern of operating losses typical for clinical-stage biotech firms without approved products or revenue. Cash runway and clinical outcomes remain key near-term value drivers.